Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2006

Open Access 01-12-2006 | Research article

Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer

Authors: Jens Kollermann, Carsten Kempkensteffen, Burkhard Helpap, Mark Schrader, Hans Krause, Markus Muller, Kurt Miller, Martin Schostak

Published in: BMC Urology | Issue 1/2006

Login to get access

Abstract

Background

In spite of excellent cure rates for prostate cancer patients with favorable tumor characteristics, patients with unfavorable characteristics after radical prostatectomy are still at a significantly increased risk of tumor progression. Early adjuvant hormonal therapy (AHT) has been shown to be of prognostic benefit in these patients. Unfortunately initiation and duration of early AHT in the individual patient is based on statistic data. PSA, as the standard prostate marker is neither able to reliably indicate minimal residual tumor disease in the early postoperative phase, nor can it be used for therapy monitoring due to the suppressive effect of hormonal therapy on PSA production. Promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1-HM) has been shown to be the most common DNA alteration of primary prostatic carcinoma which, when used as a marker, is supposed to be able to overcome some of the disadvantages of PSA. However until now information on the impact of hormonal therapy on the detection of GSTP1-HM is lacking. The purpose of our study was to assess the impact of endocrine therapy on the detection of GSTP1-HM by methylation-specific PCR (MSP) in prostate cancer.

Methods

Paraffin embedded tumor samples from the radical prostatectomy (RP) specimens from 15 patients after hormonal therapy (HT) (mean 8 months) were assessed by MSP. In 8 of the patients the GSTP-1 status of the tumors before HT was assessed on the corresponding initial diagnostic biopsies.

Results

Following HT MSP showed GSTP1-HM in 13/15 of the RP specimens. In two patients analysis of the RP specimens failed to show GSTP1-HM. All initial tumor samples (8/8 biopsy specimens) showed GSTP1-HM, including both patients negative for GSTP1 HM in the corresponding RP specimen.

Conclusion

In most cases hormonal therapy appears to not alter GSTP1 HM detection. However the change from a positive to a negative GSTP1 HM status in a subset of the patients may point to an, at least partial androgen dependency. Further studies on a larger cohort of patients are necessary to assess its frequency and the exact hormonal interactions.
Appendix
Available only for authorised users
Literature
1.
Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001, 58 (3): 417-424. 10.1016/S0090-4295(01)01264-X.CrossRefPubMed
2.
Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001, 28 (3): 555-565. 10.1016/S0094-0143(05)70163-4.CrossRefPubMed
3.
Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol. 2004, 172 (5 Pt 1): 1865-1870. 10.1097/01.ju.0000140159.94703.80.CrossRefPubMed
4.
Bastian PJ, Nakayama M, De Marzo AM, Nelson WG: [GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer]. Urologe A. 2004, 43 (5): 573-579. 10.1007/s00120-004-0540-7.CrossRefPubMed
5.
Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, Miller K: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000, 60 (21): 5941-5945.PubMed
6.
Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader M, Miller K: DNA-based detection of prostate cancer in urine after prostatic massage. Urology. 2001, 58 (3): 335-338. 10.1016/S0090-4295(01)01268-7.CrossRefPubMed
7.
Goessl C, Muller M, Miller K: Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis. 2000, 3 (S1): S17-10.1038/sj.pcan.4500441.CrossRefPubMed
8.
Kollermann J, Muller M, Goessl C, Krause H, Helpap B, Pantel K, Miller K: Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. Eur Urol. 2003, 44 (5): 533-538. 10.1016/S0302-2838(03)00361-0.CrossRefPubMed
9.
Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994, 91 (24): 11733-11737. 10.1073/pnas.91.24.11733.CrossRefPubMedPubMedCentral
10.
Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R: Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005, 11 (18): 6582-6588. 10.1158/1078-0432.CCR-05-0658.CrossRefPubMed
11.
Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992, 89 (5): 1827-1831. 10.1073/pnas.89.5.1827.CrossRefPubMedPubMedCentral
12.
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996, 93 (18): 9821-9826. 10.1073/pnas.93.18.9821.CrossRefPubMedPubMedCentral
13.
Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D: Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst. 2001, 93 (22): 1747-1752. 10.1093/jnci/93.22.1747.CrossRefPubMed
14.
Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG: Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res. 2005, 11 (11): 4037-4043. 10.1158/1078-0432.CCR-04-2446.CrossRefPubMed
15.
Helpap B, Bocking A, Dhom G, Faul P, Kastendieck H, Leistenschneider W, Muller HA: [Classification, histologic and cytologic grading and regression grading of prostate cancer]. Urologe A. 1985, 24 (3): 156-159.PubMed
Metadata
Title
Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer
Authors
Jens Kollermann
Carsten Kempkensteffen
Burkhard Helpap
Mark Schrader
Hans Krause
Markus Muller
Kurt Miller
Martin Schostak
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2006
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-6-15

Other articles of this Issue 1/2006

BMC Urology 1/2006 Go to the issue

Case report

Primary PEComa of the bladder treated with primary excision and adjuvant interferon-alpha immunotherapy: a case report

Research article

Little effects of Insulin-like Growth Factor-I on testicular atrophy induced by hypoxia

Research article

Inflammation and enhanced nociceptive responses to bladder distension produced by intravesical zymosan in the rat

Research article

Factors affecting calcium oxalate dihydrate fragmented calculi regrowth

Research article

Epidemiology of complications of male circumcision in Ibadan, Nigeria

Research article

Intraprostatic injection of botulinum toxin type- A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs